Download PDF
Horm Metab Res 2002; 34(6): 279-287
DOI: 10.1055/s-2002-33255
Original Basic
© Georg Thieme Verlag Stuttgart · New York

A Novel Approach Using Transcomplementing Adenoviral Vectors for Gene Therapy of Adrenocortical Cancer

G.  W.  Wolkersdörfer 4 , S.  R.  Bornstein 1, 5 , J.  N.  Higginbotham 3 , N.  Hiroi 1 , J.  J.  Vaquero 2 , M.  V.  Green 2 , R.  M.  Blaese 3 , G.  Aguilera 1 , G.  P.  Chrousos 1 , W.  J.  Ramsey 3
  • 1Developmental Endocrinology Branch, National Institute of Child Health and Human Development
  • 2Nuclear Medicine Department, Warren Grant Magnuson Clinical Center
  • 3Clinical Gene Therapy Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland USA
  • 4Medical Department I, Technical University of Dresden
  • 5Department of Endocrinology, University of Düsseldorf, Germany
This work was supported in part by a grant from Studienstiftung des Deutschen Volkes and BASF AG to G.W.W. and a Heisenberg grant to S.R.B.
Further Information

Publication History

Received 5 February 2002

Accepted after Revision 11 March 2002

Publication Date:
12 August 2002 (online)

Also available at
    Permissions and Reprints

Abstract

Current therapies for adrenocortical carcinomas do not improve the life expectancy of patients. In this study, we tested whether a gene-transfer therapy based upon a suicide gene/prodrug system would be effective in an animal model of the disease. We employed E4- and E1A/B-depleted, herpes simplex virus-thymidine kinase-expressing adenoviral mutants that transcomplement each other within tumor cells, hereby improving transgene delivery and efficacy by viral replication in situ. Transcomplementation of vectors increased the fraction of transduced of tumor cells. This increase was accompanied by greater tumor volume reduction compared to non-transcomplementing approaches. Survival time improved with non-replicating vectors plus GCV compared to controls. However, transcomplementation/replication of vectors led to a further significant increment in anti-tumor activity and survival time (p < 0.02). In treated animals, we observed a high number of apoptotic nuclei both adjacent to and distant from injection sites and sites of viral oncolysis. Ultrastructural analyses exhibited nuclear inclusion bodies characteristic of virus production in situ, and provided further evidence that this therapy induced apoptotic cell death within tumor cells. We conclude that the efficacy of suicide gene therapy is significantly amplified by viral replication and, in combination with GCV, significantly reduces tumor burden and increases survival time.

Key words

Adrenal Gland - Cancer - Gene Therapy - Adenovirus - Transcomplementing - Bicistronic

References

  • 1 Harrison L E, Gaudin P B, Brennan M F. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection.  Arch Surg. 1999;  134 181-185
    PubMedGoogle Scholar
  • 2 Mayer S K, Oligny L L, Deal C, Yazbeck S, Gagne N, Blanchard N. Childhood adrenocortical tumors: case series and reevaluation of prognosis - a 24-year experience.  J Pediatr Surg. 1997;  32 911-915
    CrossrefPubMedGoogle Scholar
  • 3 Teinturier C, Pauchard M S, Brugieres L, Landais P, Chaussain J L, Bougneres P F. Clinical and prognostic aspects of adrenocortical neoplasms in childhood.  Med Pediatr Oncol. 1999;  32 106-111
    CrossrefPubMedGoogle Scholar
  • 4 Bornstein S R, Stratakis C A, Chrousos G P. Adrenocortical tumors: recent advances in basic concepts and clinical management.  Ann Intern Med. 1999;  130 759-771
    PubMedGoogle Scholar
  • 5 Marx C, Wolkersdörfer G W, Brown J W, Scherbaum W A, Bornstein S R. MHC class II expression - a new tool to assess dignity in adrenocortical tumours.  J Clin Endocrinol Metab. 1996;  81 4488-4491
    CrossrefPubMedGoogle Scholar
  • 6 Willenberg H S, Stratakis C A, Marx C, Ehrhart-Bornstein M, Chrousos G P, Bornstein S R. Aberrant interleukin-1 receptors in a cortisol-secreting adrenal adenoma causing Cushing’s syndrome.  N Engl J Med. 1998;  339 27-31
    CrossrefPubMedGoogle Scholar
  • 7 Hogan T F, Citrin D L, Johnson B M, Nakamura S, Davis T E, Borden E C. o,p’-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.  Cancer. 1978;  42 2177-2181
    PubMedGoogle Scholar
  • 8 Schteingart D E, Sinsheimer J E, Counsell R E, Abrams G D, McClellan N, Djanegara T, Hines J, Ruangwises N, Benitez R, Wotring L L. Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma.  Cancer Chemother Pharmacol. 1993;  31 459-466
    CrossrefPubMedGoogle Scholar
  • 9 Zidan J, Shpendler M, Robinson E. Treatment of metastatic adrenal cortical carcinoma with etoposide (VP- 16) and cisplatin after failure with o,p’DDD. Clinical case reports.  Am J Clin Oncol. 1996;  19 229-231
    CrossrefPubMedGoogle Scholar
  • 10 Fekete E, Little C C. Histological study of adrenal cortical carcinoma in gonadectomized mice of the ce strain.  Cancer Res. 1945;  5 220-226
    PubMedGoogle Scholar
  • 11 El Bolkainy M N, Pierce G BJ, French A J. Regression of an adrenal cortical carcinoma by estradiol treatment.  Cancer Res. 1967;  27 1846-1854
    PubMedGoogle Scholar
  • 12 Leibovitz A, McCombs W M, Johnston D, McCoy C E, Stinson J C. New human cancer cell culture lines. I. SW-13, small-cell carcinoma of the adrenal cortex.  J Natl Cancer Inst. 1973;  51 691-697
    PubMedGoogle Scholar
  • 13 Danesi R, Agen C, Bernardini N, Costa M, Del Tacca M. The antiproliferative effect of suramin on the cancer cell line SW-13 is mediated by the inhibition of transforming growth factor beta 1 (TGF- beta 1).  Pharmacol Res. 1992;  25 Suppl. 1 17-18
    PubMedGoogle Scholar
  • 14 La Rocca R V, Stein C A, Danesi R, Jamis-Dow C A, Weiss G H, Myers C E. Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect.  J Clin Endocrinol Metab. 1990;  71 497-504
    PubMedGoogle Scholar
  • 15 Wu Y W, Chik C L, Knazek R A. An in vitro and in vivo study of antitumor effects of gossypol on human SW-13 adrenocortical carcinoma.  Cancer Res. 1989;  49 3754-3758
    PubMedGoogle Scholar
  • 16 Verma I M, Somia N. Gene therapy - promises, problems and prospects (news).  Nature. 1997;  389 239-242
    CrossrefPubMedGoogle Scholar
  • 17 Nanni P, Forni G, Lollini P L. Cytokine gene therapy: hopes and pitfalls.  Ann Oncol. 1999;  10 261-266
    PubMedGoogle Scholar
  • 18 Asselin-Paturel C, Lassau N, Guinebretiere J M, Zhang J, Gay F, Bex F, Hallez S, Leclere J, Peronneau P, Mami-Chouaib F, Chouaib S. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography (In Process Citation).  Gene Ther. 1999;  6 606-615
    CrossrefPubMedGoogle Scholar
  • 19 Cao Y, O’Reilly M S, Marshall B, Flynn E, Ji R W, Folkman J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases.  J Clin Invest. 1998;  101 1055-1063
    PubMedGoogle Scholar
  • 20 Lin P, Buxton J A, Acheson A, Radziejewski C, Maisonpierre P C, Yancopoulos G D, Channon K M, Hale L P, Dewhirst M W, George S E, Peters K G. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl.  Acad Sci USA. 1998;  95 8829-8834
    PubMedGoogle Scholar
  • 21 Tanaka T, Manome Y, Wen P, Kufe D W, Fine H A. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth.  Nat Med. 1997;  3 437-442
    CrossrefPubMedGoogle Scholar
  • 22 Moolten F L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy.  Cancer Res. 1986;  46 5276-5281
    PubMedGoogle Scholar
  • 23 Moolten F L, Wells J M. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors.  J Natl Cancer Inst. 1990;  82 297-300
    CrossrefPubMedGoogle Scholar
  • 24 Bi W L, Parysek L M, Warnick R, Stambrook P J. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy.  Hum Gene Ther. 1993;  4 725-731
    PubMedGoogle Scholar
  • 25 Ishii-Morita H, Agbaria R, Mullen C A, Hirano H, Koeplin D A, Ram Z, Oldfield E H, Johns D G, Blaese R M. Mechanism of “bystander effect” killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment.  Gene Ther. 1997;  4 244-251
    CrossrefPubMedGoogle Scholar
  • 26 Touraine R L, Ishii-Morita H, Ramsey W J, Blaese R M. The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication.  Gene Ther. 1998;  5 1705-1711
    CrossrefPubMedGoogle Scholar
  • 27 Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl.  Acad Sci USA. 1996;  93 1831-1835
    PubMedGoogle Scholar
  • 28 Caplen N J, Higginbotham J N, Scheel J R, Vahanian N, Yoshida Y, Hamada H, Blaese R M, Ramsey W J. Adeno-retroviral chimeric viruses as in vivo transducing agents.  Gene Ther. 1999;  6 454-459
    CrossrefPubMedGoogle Scholar
  • 29 Bischoff J R, Kirn D H, Williams A, Heise C, Horn S, Muna M, Ng L, Nye J A, Sampson-Johannes A, Fattaey A, McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells (see comments).  Science. 1996;  274 373-376
    CrossrefPubMedGoogle Scholar
  • 30 Wildner O, Morris J C, Vahanian N N, Ford H J, Ramsey W J, Blaese R M. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer.  Gene Ther. 1999;  6 57-62
    CrossrefPubMedGoogle Scholar
  • 31 Heise C, Sampson-Johannes A, Williams A, McCormick F, von Hoff D D, Kirn D H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.  Nat Med. 1997;  3 639-645
    PubMedGoogle Scholar
  • 32 Brand K, Arnold W, Bartels T, Lieber A, Kay M A, Strauss M, Dorken B. Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors.  Cancer Gene Ther . 1997;  4 9-16
    PubMedGoogle Scholar
  • 33 van der Eb M M, Cramer S J, Vergouwe Y, Schagen F H, van Krieken J H, van der Eb A J, Rinkes I H, van de Velde C J, Hoeben R C. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration.  Gene Ther. 1998;  5 451-458
    CrossrefPubMedGoogle Scholar
  • 34 Bridge E, Medghalchi S, Ubol S, Leesong M, Ketner G. Adenovirus early region 4 and viral DNA synthesis.  Virology. 1993;  193 794-801
    CrossrefPubMedGoogle Scholar
  • 35 Graham F L, Smiley J, Russell W C, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5.  J Gen Virol. 1977;  36 59-74
    PubMedGoogle Scholar
  • 36 Lozier J N, Yankaskas J R, Ramsey W J, Chen L, Berschneider H, Morgan R A. Gut epithelial cells as targets for gene therapy of hemophilia.  Hum Gene Ther. 1997;  8 1481-1490
    PubMedGoogle Scholar
  • 37 Graham F L, Harrison T, Williams J. Defective transforming capacity of adenovirus type 5 host-range mutants.  Virology . 1978;  86 10-21
    CrossrefPubMedGoogle Scholar
  • 38 Okada T, Ramsey W J, Munir J, Wildner O, Blaese R M. Efficient directional cloning of recombinant adenovirus vectors using DNA-protein complex.  Nucleic Acids Res. 1998;  26 1947-1950
    CrossrefPubMedGoogle Scholar
  • 39 Barth R JJ, Bock S N, Mulé J J, Rosenberg S A. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes.  J Immunol. 1990;  144 1531-1537
    PubMedGoogle Scholar
  • 40 Shtrichman R, Kleinberger T. Adenovirus type 5 E4 open reading frame 4 protein induces apoptosis in transformed cells.  J Virol. 1998;  72 2975-2982
    PubMedGoogle Scholar
  • 41 Marcellus R C, Lavoie J N, Boivin D, Shore G C, Ketner G, Branton P E. The early region 4orf4 protein of human adenovirus type 5 induces p53-independent cell death by apoptosis.  J Virol. 1998;  72 7144-7153
    PubMedGoogle Scholar
  • 42 Alemany R, Lai S, Lou Y C, Jan H Y, Fang X, Zhang W W. Complementary adenoviral vectors for oncolysis.  Cancer Gene Ther. 1999;  6 21-25
    CrossrefPubMedGoogle Scholar
  • 43 Heise C C, Williams A M, Xue S, Propst M, Kirn D H. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy.  Cancer Res. 1999;  59 2623-2628
    PubMedGoogle Scholar
  • 44 Wildner O, Blaese R M, Morris J C. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase.  Cancer Res. 1999;  59 410-413
    PubMedGoogle Scholar
  • 45 Trosko J E, Ruch R J. Cell-cell communication in carcinogenesis.  Front Biosci. 1998;  3 D208-D236
    PubMedGoogle Scholar
  • 46 Yamasaki H, Krutovskikh V, Mesnil M, Tanaka T, Zaidan-Dagli M L, Omori Y. Role of connexin (gap junction) genes in cell growth control and carcinogenesis.  CR Acad Sci III . 1999;  322 151-159
    PubMedGoogle Scholar
  • 47 Murray S A, Fishman L A, Brown J, Bornstein S R. Alpha1 connexin 43 gap junctions are decreased in human adrenocortical tumors.  J Clin Endocrinol Metab. 2000;  85 890-895
    CrossrefPubMedGoogle Scholar
  • 48 Touraine R L, Vahanian N, Ramsey W J, Blaese R M. Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions.  Hum Gene Ther. 1998;  9 2385-2391
    PubMedGoogle Scholar
  • 49 Wolkersdörfer G W, Marx C, Brown J W, Scherbaum W A, Bornstein S R. Evaluation of apoptotic parameters in normal and neoplastic human adrenal.  Endocr Res. 1996;  22 411-419
    PubMedGoogle Scholar
  • 50 Wolkersdörfer G W, Lohmann T, Marx C, Schröder S, Pfeiffer R, Stahl H-D, Scherbaum W A, Chrousos G P, Bornstein S R. Lymphocytes stimulate dehydroepiandrosterone production through direct cellular contact with adrenal zona reticularis cells: A novel mechanism of immune-endocrine interaction.  J Clin Endocrinol Metab. 1999;  84 4220-4227
    CrossrefPubMedGoogle Scholar
  • 51 Lozier J N, Metzger M E, Donahue R E, Morgan R A. The rhesus macaque as an animal model for hemophilia B gene therapy.  Blood. 1999;  93 1875-1881
    PubMedGoogle Scholar
  • 52 Medghalchi S, Padmanabhan R, Ketner G. Early region 4 modulates adenovirus DNA replication by two genetically separable mechanisms.  Virology. 1997;  236 8-17
    CrossrefPubMedGoogle Scholar
  • 53 Bondesson M, Ohman K, Manervik M, Fan S, Akusjärvi G. Adenovirus E4 open reading frame 4 protein autoregulates E4 transcription by inhibiting E1A transactivation of the E4 promoter.  J Virol. 1996;  70 3844-3851
    PubMedGoogle Scholar
  • 54 Kleinberger T, Shenk T. Adenovirus E4orf4 protein binds to protein phosphatase 2A, and the complex down regulates E1A-enhanced junB transcription.  J Virol. 1993;  67 7556-7560
    PubMedGoogle Scholar
  • 55 Müller U, Kleinberger T, Shenk T. Adenovirus E4orf4 protein reduces phosphorylation of c-Fos and E1A proteins while simultaneously reducing the level of AP-1.  J Virol. 1992;  66 5867-5878
    PubMedGoogle Scholar
  • 56 Williams J, Grodzicker T, Sharp P, Sambrook J. Adenovirus recombination: Physical mapping of crossover events.  Cell. 1975;  4 113-119
    CrossrefPubMedGoogle Scholar

G. W. Wolkersdörfer

Medical Department I · Faculty of Medicine Carl Gustav Carus · Technical University of Dresden

Fetscherstr. 74 · 01307 Dresden · Germany ·

Phone: + 49 (351) 458-2610

Fax: + 49 (351) 458-4394